Response to Letter to the Editor from Hao and Xue: “Checkpoint Inhibitor-associated Autoimmune Diabetes Mellitus Is Characterized by C-Peptide Loss and Pancreatic Atrophy”-Reference-Cited by-同舟云学术

Response to Letter to the Editor from Hao and Xue: “Checkpoint Inhibitor-associated Autoimmune Diabetes Mellitus Is Characterized by C-Peptide Loss and Pancreatic Atrophy”

Published:2024-08-13 Issue: Volume: Page:
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Wu Linda¹²³⁴^ORCID,Carlino Matteo Salvatore²⁴⁵,Brown David Alexander¹²⁴⁶,Long Georgina Venetia⁴⁵⁷,Clifton-Bligh Roderick³⁴^ORCID,Mellor Rhiannon²,Moore Krystal²,Sasson Sarah Christina²⁴,Menzies Alexander Maxwell⁴⁵⁷,Tsang Venessa³⁴,Gunton Jenny Elizabeth¹²⁴

Affiliation:

1. Centre for Diabetes and Endocrinology, Westmead Institute for Medical Research , Westmead, NSW 2145 , Australia

2. Westmead Hospital , Westmead, NSW 2145 , Australia

3. Department of Endocrinology, Royal North Shore Hospital , St Leonards, NSW 2065 , Australia

4. Faculty of Medicine and Health, University of Sydney , Camperdown, NSW 2050 , Australia

5. Melanoma Institute Australia, The Poche Centre , Wollstonecraft, NSW 2065 , Australia

6. Institute of Clinical Pathology and Medical Research, NSW Health Pathology , Westmead, NSW 2145 , Australia

7. Department of Medical Oncology, Royal North Shore Hospital , St Leonards, NSW 2065 , Australia

Publisher

The Endocrine Society

Link

https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgae555/58935541/dgae555.pdf

Reference5 articles.

1. Letter to the Editor from Hao and Xue: “Checkpoint inhibitor-associated autoimmune diabetes mellitus is characterized by C-peptide loss and pancreatic atrophy”;Hao;J Clin Endocrinol Metab,2024

2. Checkpoint inhibitor-associated autoimmune diabetes mellitus is characterized by C-peptide loss and pancreatic atrophy;Wu;J Clin Endocrinol Metab,2024

3. Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes;Wu;Diabetes Care,2023

4. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis;Duan;JAMA Oncol,2020

5. Unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside;Wu;Front Endocrinol (Lausanne),2021